RACE-Approved CE Credit Hours: 1
Free to attend
This webinar will explore ertugliflozin as a novel therapeutic option for the management of equine hyperinsulinemia, drawing on real-world clinical experience from frontline practice. Through case examples and emerging evidence, the session will discuss patient selection, treatment protocols, monitoring strategies, and practical considerations for safe use. The focus will be on translating research into day-to-day clinical decision-making, highlighting both the successes and the challenges of using SGLT2 inhibitors in horses with metabolic disease and laminitis risk.